Products & Materials

New Products

See allHide authors and affiliations

Science  18 Nov 2016:
Vol. 354, Issue 6314, pp. 913
DOI: 10.1126/science.354.6314.913-a

LCMS Pretreatment Module

The Clinical Laboratory Automation Module (CLAM-2000) automatically performs all the processes necessary for analyzing blood and other biological samples, from scanning information from blood collection tubes to sample pretreatment and LCMS analysis. The CLAM-2000 is directly attached to the LCMS system, thus enabling a very safe, simple means for lab personnel to process and analyze samples. A variety of functions help ensure the precision of analytical results, including management of reagents, calibration curves, and controls, as well as system maintenance management. The CLAM-2000 module automatically processes individual samples successively in parallel, which gives researchers uniform pretreatment times and allows more efficient use of the mass spectrometer. By automating operations such as dispensing, stirring, filtering, heating, and sample transfer, the system effectively improves data accuracy and achieves the reproducibility needed for clinical research for new drug discovery and monitoring of drugs in the blood.

Genomic Data Analysis Software

Illumina's NGS-based CytoSeq assay extends beyond traditional microarray-based cytogenetics assays for detection of copy number variation (CNV) and absence of heterozygosity (AOH), but also adds the ability to identify single-nucleotide variation, all in a single assay. Coupled with BioDiscovery's NxClinical software for analysis and interpretation of genomic events, the new solution will offer customers a powerful and cost-effective research tool for studying CNVs, AOH, and mutations in genetic disorders. The NxClinical software will be offered with the CytoSeq assay, providing an easy-to-use, interactive instrument for visualization and interpretation of genomic events. The NxClinical software will directly read CytoSeq results to process sample data and provide results.

Inductively Coupled Plasma Optical Emission Spectrometry

The Agilent 5110 inductively coupled plasma optical emission spectrometer (ICP-OES) will enable scientists to perform faster, more precise ICP-OES analysis t The new system builds on the company's breakthrough 5100 ICP-OES, which captures axial and radial views of plasma in a single measurement, enabling laboratories to use half as much argon in the process, and saving both time and money. The new system is also a dual-view system. Unlike ICP-OES systems from other vendors, the 5110 enables laboratories to increase throughput without compromising on precision. It includes a fully integrated advanced valve system with unique hardware and software technologies that enable ultrahigh throughput with excellent precision and ease of use. IntelliQuant measurement is used for rapid sample screening and simple method development. Lastly, new diagnostic capabilities maximize instrument uptime and simplify troubleshooting.

Zika Virus Antibody

To help accelerate progress toward a vaccine or treatment for this global health threat, a Zika virus antibody from Vanderbilt University and Kerafast is now available. Thought to be the cause of microcephaly in newborn babies, the disease is spread by the mosquito genus Aedes as well as by sexual contact. By sharing data and materials research, institutions can help to address the current Zika outbreak and minimize its effects on the global population. The Zika polyclonal antibody recognizes the human Zika envelope (E) protein and can be utilized for a range of applications to study the virus and its function. Since its founding in 2011, Kerafast has partnered with more than 130 prominent academic research institutions internationally that provide thousands of rare and unique "Reagents for the Greater Good" for the benefit of the scientific community working toward the cure of disease in 52 countries on 6 continents. 

PD-1 Cell Lines

AMS Biotechnology has introduced cell lines for programmed cell death protein-1 (PD-1) research, and for testing inhibitors of the PD-1/PD-L1 (PD-ligand 1) pathway. The binding of PD-1, a receptor expressed on activated T-cells, to its ligands (PD-L1 and PD-L2) negatively regulates immune responses. PD-1 ligands are highly expressed in many cancers, and their interaction inhibits T-cell activity, allowing cancer cells to escape immune surveillance. The PD-1/PD-L pathway is also involved in regulating autoimmune responses, making these proteins therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. A PD-1/NFAT Reporter–Jurkat Cell Line is available for screening of activators or inhibitors of PD-1 signaling. An accompanying T-cell receptor activator/PD-L1–CHO Recombinant Cell Line is also designed for screening for activators or inhibitors of PD-1 signaling as well as screening PD-L1 antibodies for their binding affinity.

  • Electronically submit your new product description or product literature information! Go to www.sciencemag.org/products/newproducts.dtl for more information.

  • Newly offered instrumentation, apparatus, and laboratory materials of interest to researchers in all disciplines in academic, industrial, and governmental organizations are featured in this space. Emphasis is given to purpose, chief characteristics, and availabilty of products and materials. Endorsement by Science or AAAS of any products or materials mentioned is not implied. Additional information may be obtained from the manufacturer or supplier.

Navigate This Article